Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Global cancer statistics.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.

CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.

2.

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.

van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE.

Lancet. 2011 Jan 22;377(9762):321-31. doi: 10.1016/S0140-6736(10)62312-4.

PMID:
21247627
3.

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.

Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI.

J Clin Oncol. 2010 Sep 20;28(27):4120-8. doi: 10.1200/JCO.2009.25.9655. Epub 2010 Jun 28.

4.

Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries.

van Nes JG, Seynaeve C, Jones S, Markopoulos C, Putter H, van de Velde CJ; Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trialists., Hasenburg A, Rea DW, Vannetzel JM, Dirix L, Hozumi Y, Kerin MJ, Kieback DG, Meershoek-Klein Kranenbarg WM, Hille ET, Nortier JW.

Br J Surg. 2010 May;97(5):671-9. doi: 10.1002/bjs.6962.

PMID:
20393978
5.

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

Dezentjé VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW, Guchelaar HJ.

J Clin Oncol. 2010 May 10;28(14):2423-9. doi: 10.1200/JCO.2009.25.0894. Epub 2010 Apr 12.

PMID:
20385997
6.

Adherence with adjuvant hormonal therapy for breast cancer.

Ruddy KJ, Partridge AH.

Ann Oncol. 2009 Mar;20(3):401-2. doi: 10.1093/annonc/mdp039. No abstract available.

PMID:
19246419
7.

Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.

Ziller V, Kalder M, Albert US, Holzhauer W, Ziller M, Wagner U, Hadji P.

Ann Oncol. 2009 Mar;20(3):431-6. doi: 10.1093/annonc/mdn646. Epub 2009 Jan 15.

PMID:
19150950
8.

Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer.

Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA.

J Clin Oncol. 2008 Feb 1;26(4):549-55. Epub 2007 Dec 10.

PMID:
18071188
9.

Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology.

Wildiers H, Kunkler I, Biganzoli L, Fracheboud J, Vlastos G, Bernard-Marty C, Hurria A, Extermann M, Girre V, Brain E, Audisio RA, Bartelink H, Barton M, Giordano SH, Muss H, Aapro M; International Society of Geriatric Oncology..

Lancet Oncol. 2007 Dec;8(12):1101-15. Review.

PMID:
18054880
10.

Adherence to endocrine therapy for breast cancer.

Chlebowski RT, Geller ML.

Oncology. 2006;71(1-2):1-9. Epub 2007 Mar 5. Review.

PMID:
17344666
11.

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study..

Lancet. 2007 Feb 17;369(9561):559-70. Erratum in: Lancet. 2007 Mar 17;369(9565):906.

PMID:
17307102
12.

Early discontinuation of tamoxifen: a lesson for oncologists.

Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ.

Cancer. 2007 Mar 1;109(5):832-9.

13.

International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency.

Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M.

Eur J Cancer. 2007 Jan;43(1):14-34. Review.

PMID:
17222747
14.

Caring for older women with breast cancer: can observational research fill the clinical trial gap?

Hillner BE, Mandelblatt J.

J Natl Cancer Inst. 2006 May 17;98(10):660-1. No abstract available.

PMID:
16705114
15.

Adherence to medication.

Osterberg L, Blaschke T.

N Engl J Med. 2005 Aug 4;353(5):487-97. Review. No abstract available.

PMID:
16079372
16.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)..

Lancet. 2005 May 14-20;365(9472):1687-717.

PMID:
15894097
17.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group..

Lancet. 2005 Jan 1-7;365(9453):60-2.

PMID:
15639680
18.

Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.

Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA.

J Clin Oncol. 2004 Aug 15;22(16):3309-15.

PMID:
15310774
19.

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

Partridge AH, Wang PS, Winer EP, Avorn J.

J Clin Oncol. 2003 Feb 15;21(4):602-6.

PMID:
12586795
20.

First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.

Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS investigators..

Lancet. 2002 Sep 14;360(9336):817-24.

PMID:
12243915

Supplemental Content

Support Center